Biological Investigation of Explanted Endobronchial Lung Valves Study

NCT ID: NCT04214587

Last Updated: 2024-06-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

150 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-03-16

Study Completion Date

2027-03-02

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Rationale:

COPD is a severe, often progressive and currently incurable lung disease which affects both the upper airways (chronic bronchitis) as well as the lower airways (emphysema). In advanced stages of the disease air-trapping severely reduces the ability to breathe and subsequently the quality of life. A highly effective treatment for restoring lung mechanical functionality of these patients is the introduction of bronchoscopic lung volume reduction (BLVR), e.g. implanting small silicone/nitinol valves (EBV) inside the airways to reduce air-trapping. Although successfully investigated in a selected group of severe COPD patients, the effectiveness of the treatment can sometimes be short-lived due to fibrotic and granulation responses and tissue-material interactions.

Objective:

The main objective of this study is to study and understand the underlying biological principles of granulation and fibrotic responses limiting the effectiveness and longevity of BELVR treatment with EBVs, this to investigate the mechanism of action of tissue-device interactions.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Emphysema or COPD

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

baseline assessment group

n=150 patiënts for baseline assessment

tissue and blood sampling

Intervention Type DIAGNOSTIC_TEST

only diagnostics will be peformed

clinical need for reintervention group

n=20-30 patiënts for re-bronchoscopy

tissue and blood sampling

Intervention Type DIAGNOSTIC_TEST

only diagnostics will be peformed

clinical stable controls

n=20 stable treated control patiënts

tissue and blood sampling

Intervention Type DIAGNOSTIC_TEST

only diagnostics will be peformed

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

tissue and blood sampling

only diagnostics will be peformed

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Elidgible for EBV treatment

Exclusion Criteria

* Anticoagulation which cannot be stopped prior to the procedure
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Medical Center Groningen

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Dirk-Jan Slebos

Prof. dr. D.J. Slebos MD, PhD, Principle Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Dirk-Jan Slebos, MD PhD

Role: PRINCIPAL_INVESTIGATOR

UMC-Groningen/NL

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Medical Center Groningen

Groningen, , Netherlands

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Netherlands

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Dirk-Jan Slebos, MD PhD

Role: CONTACT

+31503616161

Jorine Hartman, PhD

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Dirk-Jan Slebos, PhD

Role: primary

Related Links

Access external resources that provide additional context or updates about the study.

http://www.bicumcg.nl

The UMC-Groningen/NL Bronchoscopic Intervention Center website

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Bio-EXCEL

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Tissue Engineering Approaches to Treat COPD
NCT04878445 ACTIVE_NOT_RECRUITING
Interstitial Lung Disease Exacerbations Study
NCT06685874 ACTIVE_NOT_RECRUITING